Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Shares of Boston Scientific (NYSE:BSX) rose nearly 7 percent in pre-market trading today after the FDA approved its Promus Element drug-eluting stent, inaugurating a head-to-head battle between the last two giants left standing in the Stent Wars.
Three former Synthes executives get prison sentences for unauthorized human trials of a Norian bone cement that led to the deaths of three patients, while a fourth still awaits sentencing after his lawyer’s collapse.
Smith & Nephew (NYSE:SNN) sued Hologic (NSDQ:HOLX) yesterday, the same day the U.S. Patent & Trademark Office granted its patent application for a "Surgical Endoscopic Cutting Device And Method For Its Use."